These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32444455)

  • 1. Statin Use Is Prospectively Associated With New-Onset Diabetes After Transplantation in Renal Transplant Recipients.
    Szili-Torok T; Bakker SJL; Tietge UJF
    Diabetes Care; 2020 Aug; 43(8):1945-1947. PubMed ID: 32444455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDL Cholesterol Efflux Predicts Incident New-Onset Diabetes After Transplantation (NODAT) in Renal Transplant Recipients Independent of HDL Cholesterol Levels.
    Szili-Torok T; Annema W; Anderson JLC; Bakker SJL; Tietge UJF
    Diabetes; 2019 Oct; 68(10):1915-1923. PubMed ID: 31375510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Serum PCSK9 Is Associated With Increased Risk of New-Onset Diabetes After Transplantation in Renal Transplant Recipients.
    Eisenga MF; Zelle DM; Sloan JH; Gaillard CAJM; Bakker SJL; Dullaart RPF
    Diabetes Care; 2017 Jul; 40(7):894-901. PubMed ID: 28461454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statin therapy is associated with the development of new-onset diabetes after transplantation in liver recipients with high fasting plasma glucose levels.
    Cho Y; Lee MJ; Choe EY; Jung CH; Joo DJ; Kim MS; Cha BS; Park JY; Kang ES
    Liver Transpl; 2014 May; 20(5):557-63. PubMed ID: 24477986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remnant lipoprotein cholesterol is associated with incident new onset diabetes after transplantation (NODAT) in renal transplant recipients: results of the TransplantLines Biobank and cohort Studies.
    Szili-Torok T; Sokooti S; Osté MCJ; Gomes-Neto AW; Dullaart RPF; Bakker SJL; Tietge UJF
    Cardiovasc Diabetol; 2022 Mar; 21(1):41. PubMed ID: 35296331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant.
    Gaynor JJ; Ciancio G; Guerra G; Sageshima J; Hanson L; Roth D; Goldstein MJ; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Barba LJ; Lopez A; Rivas J; Ruiz P; Vianna R; Burke GW
    Diabetologia; 2015 Feb; 58(2):334-45. PubMed ID: 25361829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 receptor antagonists: Protective factors against new-onset diabetes after renal transplantation.
    Xue M; Zhao C; Lv C; Chen M; Xu M; Rong R; Zhang Y; Liang J; Gao J; Yu M; Zhu T; Gao X
    J Diabetes; 2018 Nov; 10(11):857-865. PubMed ID: 29577632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multivariable risk of developing new onset diabetes after transplant-results from a single-center study of 481 adult, primary kidney transplant recipients.
    Gaynor JJ; Ciancio G; Guerra G; Sageshima J; Hanson L; Roth D; Goldstein MJ; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Barba LJ; Lopez A; Rivas J; Ruiz P; Vianna R; Burke GW
    Clin Transplant; 2015 Apr; 29(4):301-10. PubMed ID: 25581205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of insulin resistance indices in predicting new-onset diabetes after kidney transplantation.
    Nagaraja P; Ravindran V; Morris-Stiff G; Baboolal K
    Transpl Int; 2013 Mar; 26(3):273-80. PubMed ID: 23230898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins).
    Prasad GV; Kim SJ; Huang M; Nash MM; Zaltzman JS; Fenton SS; Cattran DC; Cole EH; Cardella CJ
    Am J Transplant; 2004 Nov; 4(11):1897-903. PubMed ID: 15476492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New-onset diabetes after transplantation: drug-related risk factors.
    Santos L; Rodrigo E; Piñera C; Quintella E; Ruiz JC; Fernández-Fresnedo G; Palomar R; Gómez-Alamillo C; de Francisco A; Arias M
    Transplant Proc; 2012 Nov; 44(9):2585-7. PubMed ID: 23146462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-transplantation glucose testing for predicting new-onset diabetes mellitus after renal transplantation.
    Ramesh Prasad GV; Huang M; Bandukwala F; Nash MM; Rapi L; Montada-Atin T; Meliton G; Zaltzman JS
    Clin Nephrol; 2009 Feb; 71(2):140-6. PubMed ID: 19203506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors and long-term consequences of new-onset diabetes after renal transplantation.
    Tomkins M; Tudor RM; Cronin K; O'Kelly P; Williams Y; Little D; de Freitas DG; Denton M; O'Seaghdha C; Conlon P; Smith D
    Ir J Med Sci; 2020 May; 189(2):497-503. PubMed ID: 31631244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypomagnesemia and increased risk of new-onset diabetes mellitus after transplantation in pediatric renal transplant recipients.
    Hayes W; Boyle S; Carroll A; Bockenhauer D; Marks SD
    Pediatr Nephrol; 2017 May; 32(5):879-884. PubMed ID: 28039534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of Statin-Associated Adverse Events in Kidney Transplant Recipients.
    Bae S; Ahn JB; Joseph C; Whisler R; Schnitzler MA; Lentine KL; Kadosh BS; Segev DL; McAdams-DeMarco MA
    Clin J Am Soc Nephrol; 2023 May; 18(5):626-633. PubMed ID: 36800538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and risk factors for development of new-onset diabetes after kidney transplantation.
    Bee YM; Tan HC; Tay TL; Kee TY; Goh SY; Kek PC
    Ann Acad Med Singap; 2011 Apr; 40(4):160-7. PubMed ID: 21678001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation.
    Porrini E; Delgado P; Alvarez A; Cobo M; Pérez L; González-Posada JM; Hortal L; Gallego R; García JJ; Checa M; Morales A; Salido E; Hernández D; Torres A
    Nephrol Dial Transplant; 2008 Apr; 23(4):1436-41. PubMed ID: 18029372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New onset diabetes after kidney transplantation in autosomal dominant polycystic kidney disease: a retrospective cohort study.
    Ruderman I; Masterson R; Yates C; Gorelik A; Cohney SJ; Walker RG
    Nephrology (Carlton); 2012 Jan; 17(1):89-96. PubMed ID: 21854501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of preoperative hepatitis B virus infection, hepatitis C virus infection, and coinfection on the development of new-onset diabetes after kidney transplantation.
    Liang J; Lv C; Chen M; Xu M; Zhao C; Yang Y; Wang J; Zhu D; Gao J; Rong R; Zhu T; Yu M
    J Diabetes; 2019 May; 11(5):370-378. PubMed ID: 30203544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus.
    Elens L; Sombogaard F; Hesselink DA; van Schaik RH; van Gelder T
    Pharmacogenet Genomics; 2013 Dec; 23(12):649-57. PubMed ID: 24113216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.